Hylarides; Mark D.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Hylarides; Mark D..The latest application filed is for "high dose radionuclide complexes for bone marrow treatment".

Company Profile

0.11.11

Hylarides; Mark D. - Stanwood WA
Hylarides, Mark D. - Mukilteo WA
Hylarides; Mark D. - Snohomish County WA
Hylarides; Mark D. - Snohmoish County WA
Hylarides; Mark D. - Everett WA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
High dose radionuclide complexes for bone marrow treatment Grant 7,696,331 - Fritzberg , et al. April 13, 2	2010-04-13
High Dose Radionuclide Complexes For Bone Marrow Treatment App 20090136419 - Fritzberg; Alan R. ; et al.	2009-05-28
Methods Of Use Of Antibodies With Reduced Immunogenicity Or Toxicity App 20090094715 - Graves; Scott S. ; et al.	2009-04-09
Treatment of bone-associated cancers Grant 7,408,046 - Fritzberg , et al. August 5, 2	2008-08-05
High dose radionuclide complexes for bone marrow suppression Grant 7,378,077 - Fritzberg , et al. May 27, 2	2008-05-27
High dose radionuclide complexes for bone marrow suppression App 20070053833 - Fritzberg; Alan R. ; et al.	2007-03-08
High dose radionuclide complexes for bone marrow suppression Grant 7,097,823 - Fritzberg , et al. August 29, 2	2006-08-29
High dose radionuclide complexes for bone marrow suppression Grant 7,070,759 - Fritzberg , et al. July 4, 2	2006-07-04
High dose radionuclide complexes for bone marrow suppression App 20050238578 - Fritzberg, Alan R. ; et al.	2005-10-27
High dose radionuclide complexes for bone marrow suppression App 20050129667 - Fritzberg, Alan R. ; et al.	2005-06-16
Methods of use of antibodies with reduced immunogenicity or toxicity App 20050100545 - Graves, Scott S. ; et al.	2005-05-12
High dose radionuclide complexes for bone marrow suppression App 20050063905 - Fritzberg, Alan R. ; et al.	2005-03-24
Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods App 20050008635 - Graves, Scott S. ; et al.	2005-01-13
Pretargeting methods and compounds App 20040241172 - Axworthy, Donald B. ; et al.	2004-12-02
High dose radionuclide complexes for bone marrow suppression Grant 6,767,531 - Fritzberg , et al. July 27, 2	2004-07-27
Method of reducing immunogenicity of toxicity of an antibody of IgG class App 20030119078 - Graves, Scott S. ; et al.	2003-06-26
High dose radionuclide complexes for bone marrow suppression App 20020176818 - Fritzberg, Alan R. ; et al.	2002-11-28
Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 Grant 6,358,710 - Graves , et al. March 19, 2	2002-03-19
Cleavable conjugates for the delivery and release of agents in native form Grant 5,563,250 - Hylarides , et al. October 8, 1	1996-10-08
Methods for isolating compounds using cleavable linker bound matrices Grant 5,141,648 - Hylarides , et al. August 25, 1	1992-08-25
Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents Grant 5,057,301 - Wilbur , et al. October 15, 1	1991-10-15
Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound Grant 5,017,693 - Hylarides , et al. May 21, 1	1991-05-21

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.